PRIMARA: A Prospective Descriptive Observational Study to Review Mimpara (Cinacalcet) Use in Patients With Primary Hyperparathyroidism in Clinical Practice

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

305 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-10-31

Study Completion Date

2012-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multicentre, descriptive observational study of adult patients with primary HPT receiving cinacalcet in clinical practice in a number of countries in Europe. Patients will be enrolled within 1 month of initiating cinacalcet treatment, and data will be collected prospectively for up to 1 year from initiation. Data will continue to be collected from patients discontinuing cinacalcet before the end of this period.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism

NCT02525796

Primary Hyperparathyroidism

COMPLETED PHASE2/PHASE3

Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.

NCT03027557

Primary Hyperparathyroidism Parathyroid Adenoma Parathyroid Hyperplasia

COMPLETED PHASE3

Denosumab in Primary Hyperparathyroidism

NCT01558115

Primary Hyperparathyroidism

TERMINATED PHASE4

Oral PTH(1-34) PK and PD Study in Patients With Hypoparathyroidism

NCT03516773

Hypoparathyroidism

COMPLETED PHASE2

One Week Comparison Study of PTH and PTHrP Infusions

NCT01333267

Osteoporosis Hypercalcemia of Malignancy Hyperparathyroidism +1 more

WITHDRAWN PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hyperparathyroidism, Primary

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cinacalcet

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cinacalcet

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* at least 18 years of age at the time of first administration of cinacalcet
* patients with primary HPT who have initiated cinacalcet within 1 month before enrolment in the study
* provision of informed consent (if required)

Exclusion Criteria

* previous use of cinacalcet (other than within 1 month before enrolment)
* diagnosed secondary HPT
* other known aetiology of hypercalcaemia (eg, sarcoidosis, tuberculosis)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No